Clinical Drug Trial Reporting Failures May Have a Blockchain Solution

Clinical Drug Trial Reporting Failures May Have a Blockchain Solution

A recent issue of the prestigious British Medical Journal (BMJ) which focused on the reporting of clinical drug trials was, in their own words, “…filled with tales of failure.”

In the same report, the BMJ highlighted “…that half of clinical trials in the European Union Clinical Trials Register (EUCTR) failed to report results within 12 months of completion, as required by EU rules.”


The problem is not restricted to the EU, with the BMJ’s US counterpart, the American Journal of Medicine, making similar observations in reference to a number of trials featuring on the register.

Reporting rates of trials conducted by non-commercial sponsors, such as universities or charities, faired particularly poorly when compared with trials sponsored by pharmaceutical or device companies.

While the EUCTR study was detailed, the authors stopped short of drawing firm conclusions but suggested that non-commercial sponsors in particular may “…lack administrative procedures to flag breaches and support compliance among their researchers. They may also lack clear lines of responsibility…”

It is clear from the data collected that project management, as well as compliance and reporting procedures, were questionable in a number of the clinical trials studied.

One ICO on the horizon, ClinTex, has stepped forward to propose a start-to-finish blockchain solution in this specialised area.

With a range of analytical and data dApps available through their Ethereum-based Clinical Trials Intelligence (CTi) platform, ClinTex seem to have known of the weakness of non-commercial providers in particular and, according to their white-paper, have partnered with Intellimed in order to “…deploy the CTi platform in academic clinical research settings.”

The project team is hoping to leverage blockchain-based incentives as a means to encouraging improved compliance amongst researchers where it is thought that an explosion in the number of medical researchers over the last decade may have been responsible for a drop in standards in at least some areas of medical research.